PUBLISHER: The Business Research Company | PRODUCT CODE: 1680372
PUBLISHER: The Business Research Company | PRODUCT CODE: 1680372
A pharmaceutical drug is a substance designed for the treatment, prevention, or alleviation of an illness, condition, or its symptoms. These substances can be administered through various methods, including oral consumption, skin patches, injections, or inhalation. Notable pharmaceuticals derived from natural sources encompass vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics.
The primary categories of pharmaceutical drugs cover a wide spectrum, including cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are specifically tailored to address medical conditions related to the heart or circulatory system, such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. These drugs can be administered through various routes, including oral and parenteral methods, and are categorized as branded or generic drugs. The acquisition of pharmaceutical drugs can occur through prescription-based or over-the-counter channels, with distribution taking place through hospital pharmacies, retail pharmacies/drug stores, and other outlets.
The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The pharmaceutical drugs market size has grown strongly in recent years. It will grow from $1747.07 billion in 2024 to $1864.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to rise in healthcare awareness, increased prevalence of respiratory diseases, changes in lifestyles, increase in pharmaceutical research and development (R&D) expenditure, increasing aging population, increased number of surgical procedures, strong economic growth in emerging markets and increased number of approvals for hematology/oncology (cancer) drugs.
The pharmaceutical drugs market size is expected to see strong growth in the next few years. It will grow to $2384.53 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing government support, increase in healthcare access, increase in investments, rapid growth in elderly population, rise in healthcare expenditure and rising awareness on immunization and vaccination. Major trends in the forecast period include use of biomarkers for drug development, increased development of next generation biologics, increased focus on personalized medicine, investment in artificial intelligence (AI) for drugs discovery, combination drug therapy to treat respiratory diseases, partnerships with wearables companies to improve drug research and development, use of 3D printing technology in drug manufacturing, microneedle pills to improve and enhance drug delivery and development of vaccines using MRNA.
The increase in sedentary jobs, busy lifestyles, and evolving consumer preferences is impacting the global disease landscape, particularly the prevalence of non-communicable diseases such as cancer, diabetes, and cardiovascular conditions. Factors such as prolonged working hours, reduced physical activity, and unhealthy dietary habits contribute significantly to chronic diseases such as diabetes. According to the World Health Organization, noncommunicable diseases (NCDs) account for 41 million deaths annually, representing 74% of global mortality. This trend underscores the growing demand for biologic drugs to address conditions such as diabetes. These factors are anticipated to expand the global patient population, thereby fostering growth in the pharmaceutical drug market throughout the forecast period.
The rising incidence of rare diseases is anticipated to drive growth in the pharmaceutical drug market in the future. A rare disease is characterized by its low prevalence, affecting only a small number of individuals compared to more common health issues. Pharmaceutical drugs play a crucial role in better managing these diseases, identifying potential therapeutics, and preventing unnecessary treatments that may have severe side effects, thus facilitating effective treatment. For example, in July 2023, the GOV.UK, a UK government department, reported that there are currently over 7,000 known rare diseases, with new ones continually being identified as research advances. Approximately 80% of these diseases have a recognized genetic basis, and it is estimated that 1 in 17 people will be affected by a rare disease at some point in their lives. Consequently, the increasing incidence of rare diseases is contributing to the growth of the pharmaceutical drug market.
Leading companies in the pharmaceutical drug market are introducing innovative medications such as Sohonos (palovarotene) capsules to establish a competitive advantage. Sohonos, a retinoid, is designed to reduce the volume of new heterotopic ossification in individuals with fibrodysplasia ossificans progressiva (FOP). For instance, in August 2023, Ipsen Biopharmaceuticals, Inc., a France-based biopharmaceutical company, unveiled Sohonos (palovarotene). This retinoid is indicated for minimizing the volume of new heterotopic ossification in adults and pediatric patients (8 years and older for females, 10 years and older for males) with FOP-a rare genetic disorder characterized by abnormal bone development in areas not typically containing bone, leading to limited movement, deformities, and severe disability.
Leading companies in the pharmaceutical drug market are launching innovative medications, such as generic cancer drugs, to enhance treatment affordability and accessibility. A generic cancer drug is defined as a medication that contains the same active ingredients, dosage, safety, strength, quality, and intended use as a brand-name cancer drug, but is usually offered at a lower price. For example, in August 2024, Lupin Limited, an India-based pharmaceutical company, introduced Doxorubicin Hydrochloride Liposome Injection in the United States. This product is a generic equivalent of Baxter Healthcare's Doxil, which is used for treating ovarian cancer, AIDS-related Kaposi's Sarcoma, and multiple myeloma. The medication is available in single-dose vials of 20 mg/10 mL and 50 mg/25 mL. This launch comes after receiving FDA approval through Lupin's alliance partner, ForDoz Pharma Corporation, and is part of Lupin's strategy to expand its oncology portfolio.
Major companies operating in the pharmaceutical drugs market include Pfizer Inc., AbbVie, Johnson & Johnson, Merck & Co, Sanofi S.A., F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb, AstraZeneca, GlaxosmithKline, Shanghai Pharmaceutical Drugs, Shanghai Fosun Pharmaceutical, Takeda Pharmaceutical Company Ltd., Otsuka Pharmaceutical Co. Ltd., Daiichi Sankyo, China National Pharmaceutical Group Co., Ltd. (Sinopharm), Shanghai Acebright Pharmaceutical Drugs Group Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd, Hanmi Pharmaceutical, Cipla Limited, Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Sun Pharma, KYORIN Holdings, Inc., Nichi-Iko Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Co.,Ltd, Kalbe Farma, Hyphens Pharma, Adjuvanz Technology Pte Ltd., Alliance Pharm Pte Ltd., Teva UK Limited, Abbott Laboratories, Vectura Group, Boehringer Ingelheim, Mylan, Zentiva, Apotex, Gilead Sciences, Bayer, Amgen, Janssen Pharmaceutica, Accord Healthcare Inc., AA Pharma Inc, Sanfer, LABORATORIOS SENOSIAIN SA DE CV (Senosiain), Siegfried Rhein, Eli Lilly & Company, Biogen, EMS Pharma, Hypermarcas, Eurofarma, Teuto Brasileiro, Biolab Farmaceutica, Cristalia, Uniao Quimica, Ache, Mantecorp Farmasa, Libbs, FQM Grupo, Spimaco, Jamjoom Pharma, Tabuk Pharmaceutical Manufacturing, Jazeera Pharmaceutical Industries, Julphar, Neopharma, Eurolab, Aspen Pharmacare Holdings Limited
North America was the largest region in the pharmaceutical drugs market in 2024. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the pharmaceutical drugs market report are Australia, China, India, Indonesia, Japan, South Korea, Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, USA, Canada, Mexico, Brazil, Chile, Argentina, Colombia, Peru, France, Germany, UK, Austria, Belgium, Denmark, Finland, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, Russia, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa
The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Pharmaceutical Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on pharmaceutical drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for pharmaceutical drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pharmaceutical drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.